Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EBIT (2021 - 2025)

Historic EBIT for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to -$1.8 million.

  • InMed Pharmaceuticals' EBIT fell 493.97% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.0 million, marking a year-over-year decrease of 1065.97%. This contributed to the annual value of -$7.9 million for FY2025, which is 304.87% up from last year.
  • As of Q3 2025, InMed Pharmaceuticals' EBIT stood at -$1.8 million, which was down 493.97% from -$1.8 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' EBIT ranged from a high of -$485150.0 in Q2 2023 and a low of -$6.5 million during Q2 2022
  • Its 5-year average for EBIT is -$2.6 million, with a median of -$2.2 million in 2023.
  • In the last 5 years, InMed Pharmaceuticals' EBIT surged by 9255.9% in 2023 and then tumbled by 31929.53% in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' EBIT stood at -$4.3 million in 2021, then soared by 48.66% to -$2.2 million in 2022, then rose by 25.7% to -$1.6 million in 2023, then plummeted by 37.03% to -$2.3 million in 2024, then increased by 19.23% to -$1.8 million in 2025.
  • Its EBIT was -$1.8 million in Q3 2025, compared to -$1.8 million in Q2 2025 and -$2.1 million in Q1 2025.